Cholinergic dysfunction in vascular dementia

被引：59

作者：

Román G.C. ^{[1
]}

机构：

[1] Department of Medicine/Neurology, Univ. of Texas Health Science Center, A. Murphy Veterans Admin. Hospital, San Antonio

来源：

Current Psychiatry Reports | 2005年 / 7卷 / 1期

关键词：

Dementia; Mild Cognitive Impairment; Vascular Dementia; Rivastigmine; Basal Forebrain;

D O I：

10.1007/s11920-005-0019-2

中图分类号：

学科分类号：

摘要：

Vascular dementia (VaD) is the second most common type of dementia in the elderly after Alzheimer's disease (AD). Evidence is presented indicating the occurrence of cholinergic dysfunction in VaD, independent from AD. Controlled clinical trials of cholinesterase inhibitors (ChEls) in VaD and in patients with AD plus cerebrovascular disease are reviewed. Compared with placebo, ChEl treatment improves cognition, behavior, and activities of daily living. Cholinergic deficits in patients with VaD may result from ischemia of basal forebrain cholinergic nuclei that are irrigated by penetrating arteries that are highly susceptible to arterial hypertension, or from ischemic lesions in basal ganglia or white matter that sever the extensive cholinergic cortical projections. Cholinergic stimulation produces increases in cortical cerebral blood flow that may be relevant to the therapeutic effect of ChEls. Copyright © 2005 by Current Science Inc.

引用

页码：18 / 26

页数：8

共 98 条

[81]

Roman G.C., Perdomo C.A., Pratt R.D., Patients with vascular dementia differ from patients with Alzheimer's disease with respect to population characteristics and pattern of cognitive decline, J. Gen. Int. Med., 18, SUPPL. 1, pp. 198-199, (2003)

[82]

Roman G.C., Perdomo C.A., Pratt R.D., Donepezil improves cognition, global function and ability to perform activities of daily living in patients with vascular dementia, J. Gen. Int. Med., 18, SUPPL. 1, (2003)

[83]

Salloway S., Pratt R.D., Perdomo C.A., A comparison of the cognitive benefits of donepezil in patients with cortical versus subcortical vascular dementia: A subanalysis of two 24-week, randomized, double-blind, placebo-controlled trials, Neurology, 60, SUPPL. 1, (2003)

[84]

Malouf R., Birks J., Donepezil for vascular cognitive impairment, Cochrane Database Syst. Rev., 1, (2004)

[85]

Loy C., Schneider L., Galantamine for Alzheimer's disease, Cochrane Database Syst. Rev., 18, (2004)

[86]

Corey-Bloom J., Galantamine: A review of its use in Alzheimer's disease and vascular dementia, Int. J. Clin. Practice, 57, pp. 219-223, (2003)

[87]

Erkinjuntti T., Kurz A., Gauthier S., Et al., Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial, Lancet, 359, pp. 1283-1290, (2002)

[88]

McKhann G., Drachman D., Folstein M., Et al., Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology, 34, pp. 939-944, (1984)

[89]

Erkinjuntti T., Kurz A., Small G.W., Et al., An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia, Clin. Ther., 25, pp. 1765-1782, (2003)

[90]

Kurz A.F., Erkinjuntti T., Small G.W., Et al., Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease, Eur. J. Neurol., 10, pp. 633-640, (2003)

← 1 2 3 4 5 6 7 8 9 10 →